Company Description
Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa.
The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow.
It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers analysis software partnerships ecosystem; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI.
It has a collaboration agreement with NeraCare that enables personalized therapy selection for early-stage melanoma patients; and license agreement with NeraCare for the development and commercialization of the immunoprint test for early-stage melanoma patient treatment decisions.
The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.
| Country | United States |
| Founded | 2015 |
| IPO Date | Apr 16, 2021 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 330 |
| CEO | Brian McKelligon |
Contact Details
Address: 100 Campus Drive, 6th Floor Marlborough, Massachusetts 01752 United States | |
| Phone | 855 896 8401 |
| Website | akoyabio.com |
Stock Details
| Ticker Symbol | AKYA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $20.00 |
| CIK Code | 0001711933 |
| CUSIP Number | 00974H104 |
| ISIN Number | US00974H1041 |
| Employer ID | 47-5586242 |
| SIC Code | 3826 |
Key Executives
| Name | Position |
|---|---|
| Brian McKelligon | President, Chief Executive Officer and Director |
| Priyam Shah | Senior Director of Business Development and Investor Relations Strategy |
| Jennifer Kamocsay | General Counsel |
| Dr. Niro Ramachandran Ph.D. | Chief Business Officer |
| Dr. Pascal Bamford Ph.D. | Senior Vice President, Research and Development and Laboratory Operations |
| Rob C. Hart CFA, J.D. | Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 13, 2024 | 8-K | Current Report |
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Nov 14, 2024 | 8-K | Current Report |
| Nov 4, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 3, 2024 | 8-K | Current Report |
| Aug 28, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Aug 6, 2024 | 10-Q | Quarterly Report |
| Aug 5, 2024 | 8-K | Current Report |
| Jun 11, 2024 | 144 | Filing |
| Jun 6, 2024 | 144 | Filing |